The histone methyltransferase NSD3 oncogene triggers ribosomal DNA transcription, interfering with FOSL2 in cancer
Open Access
- 4 May 2026
- journal article
- research article
- Published by Springer Nature in Cell Death & Disease
- Vol. 17 (1)
Abstract
Ribosome biogenesis is pervasively enhanced in cancer, and yet, how the expression of ribosomal RNA genes is triggered remains largely unknown. We found that the long isoform of the histone methyltransferase NSD3, NSD3L, one of the most frequently amplified genes in cancer, reshapes the chromatin environment surrounding ribosomal DNA (rDNA), thus triggering rRNA expression. An unbiased mass-spec approach revealed that NSD3L binds several nucleolar proteins and localizes to the nucleolus. NSD3L is essential for the binding of Polymerase I as well as of its activator UBTF (Upstream Binding Transcription Factor) to the entire rDNA locus. Conversely, NSD3L binds to a narrow sequence on rDNA located upstream of the rRNA transcription start site (TSS), displacing FOSL2, a member of the FOS/JUN transcription factor family. Upon NSD3L ablation, FOSL2 increases its binding to this region, leading to reduced rDNA expression. These results suggest a surprising, repressive role for FOSL2 on ribosomal gene expression. We also determined that NSD3L competes with another suppressor of rDNA expression, the histone methyltransferase SUV4-20H, thus impeding the deposition of the repressive histone mark H4K20me3 on rDNA. Therefore, NSD3L balances and counteracts the activities of FOSL2 and SUV4-20H on rDNA, unleashing rDNA synthesis. Accordingly, NSD3L overexpression is associated with enhanced expression of nucleolar genes in several tumor types. We hence propose NSD3L as a central epigenetic orchestrator of rRNA transcription in cancer and an enticing therapeutic target for the large group of cancers presenting with NSD3 amplifications and overexpression.Keywords
Funding Information
- Associazione Italiana per la Ricerca sul Cancro (9965)
- Associazione Italiana per la Ricerca sul Cancro (17019)
- Associazione Italiana per la Ricerca sul Cancro (31336-2024)
- Associazione Italiana per la Ricerca sul Cancro (26728-2021)
This publication has 84 references indexed in Scilit:
- NSD3: A Promising Target for Cancer TherapyCell Biochemistry and Function, 2025
- Thyroid Carcinoma with NSD3::NUTM1 Fusion: a Case with Thyrocyte Differentiation and Colloid ProductionEndocrine Pathology, 2022
- A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast CancersCancer Cell, 2018
- AP-1 Expression and its Clinical Relevance in Immune Disorders and CancerThe American Journal of the Medical Sciences, 2017
- PPAPDC1B and WHSC1L1 Are Common Drivers of the 8p11-12 Amplicon, Not Only in Breast Tumors But Also in Pancreatic Adenocarcinomas and Lung TumorsThe American Journal of Pathology, 2013
- Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53Cancer Cell, 2012
- Cancers and the NSD family of histone lysine methyltransferasesBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2011
- NSD3, a New SET Domain-Containing Gene, Maps to 8p12 and Is Amplified in Human Breast Cancer Cell LinesGenomics, 2001
- The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformationBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 1991
- Jun-B differs in its biological properties from, and is a negative regulator of, c-JunCell, 1989